Vitamin E Supplementation in Burn Patients

Burn Injury Clinical Trial

Official title:

Vitamin E Supplementation in Burn Patients

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT01413620
• Other study ID #: VitE2011
• Status: Withdrawn
• Phase: Phase 1
• Start date: August 2011
• Est. completion date: August 2021

Study information

• Verified date: September 2021
• Source: Shriners Hospitals for Children
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Burned patients because of their increased oxidative stress have severely depleted vitamin E, which is a dietary antioxidant. Oxidative stress is responsible for much of the pathophysiology seen in burned patients, which leads to acute and chronic morbidity and mortality, in addition to a decrease in their quality of life. Oral vitamin E will be used to reverse the oxidative stress of burn injury and, in the process, decrease the secondary consequences of thermal trauma. This proposal will demonstrate the benefit of maintaining adequate vitamin E status.

Description:

We have previously demonstrated that thermal injury depletes plasma vitamin E in pediatric burn patients. However, plasma changes reflect short-term vitamin E changes, whereas adipose tissue alpha-tocopherol concentrations reflect long-term vitamin E status. We reported last year that burn injury depleted vitamin E stores in adipose tissue in children by nearly half within one month following injury. Our long-term goal is to improve the quality of life of burn patients by preventing pulmonary and hepatic dysfunction that may occur from vitamin E depletion. The objectives of this application are to a) attenuate alpha-tocopherol depletion in burned patients by vitamin E supplementation, b) prevent or reverse oxidative stress in these patients, and c) collect pilot data on the effect of vitamin E supplementation on lung and liver function. Our central hypothesis is that the administration of high doses of alpha-tocopherol will prevent or restore levels of vitamin E in adipose tissue and reverse the oxidative state in burned patients. The rationale of the proposed studies is that in severe cases of vitamin E depletion, oxidative stress, fatty liver and lung dysfunction have all been reported in our patients. We will administer vitamin E supplements (300-1200 IU RRR-alpha-tocopherol) to burn subjects (n= 20 per group, 6-70 years, ≥20% total body surface burns) for fifteen days. The subjects will be randomly assigned into two groups: an early treatment group who will receive vitamin E for days 1-15 of the study, and a delayed treatment group who will receive vitamin E for days 16-30 of the study. Both groups will be studied for a total of thirty days. We will test the following aims: Aim 1: determine the degree that supplemental Vitamin E will attenuate alpha-tocopherol depletion. Aim 2: determine if supplemental Vitamin E reduces markers of oxidative stress in burned patients. Aim 3: collect preliminary data to establish the relationship between oxidative stress and pulmonary pathophysiology and fatty liver after burn injury. We will measure plasma and adipose tissue alpha-tocopherol and urinary and plasma markers of oxidative stress, prior to supplementation and then weekly. The proposed research is innovative because the oxidative stress of burn injury causes a severe depletion of an essential nutrient, vitamin E. Supplementation of vitamin E is a novel concept that may mitigate the complications of burns, including lung injury, fatty liver and peripheral neuropathy.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: August 2021
• Est. primary completion date: August 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Months to 85 Years

Eligibility

Inclusion Criteria:

• Age: 6 months - 85 years
• >20% TBSA burn

Exclusion Criteria:

• Bleeding disorders
• Positive hepatitis or HIV screens
• Pregnancy (women)

Related Conditions & MeSH terms

• Burn Injury
• Burns

Intervention

Drug:
• dl-alpha-tocopheryl acetate
Ages 6 months-1 year will receive 75 IU/day of dl-alpha-tocopheryl acetate, while ages 2-5 years will receive 150 IU/day. Ages 6-8 will receive 300 IU/day, while ages 9-13 will receive 600 IU/day, ages 14-17 will receive 800 IU/day, and ages 18-70 will receive 1200 IU/day. Vitamin E will be administered in a liquid or pill form. The dose of aqueous vitamin E (Aqueous Vitamin E Oral Drops, Silarx, No. 54838-0005-30, Spring Valley, NY) will be given orally. When/If the patient is able to eat independently, the dose of vitamin E may be given in a pill form (Novatol 5-57, No. 410217, Archer Daniels Midland Company, Decatur, IL). Depending on the subject's group, the supplement of vitamin E either will be given on days 1-15 of the study or days 16-30 of the study.

Locations

Country	Name	City	State
United States	Shriners Hospitals for Children	Galveston	Texas

Sponsors (3)

Lead Sponsor	Collaborator
Shriners Hospitals for Children	Oregon State University, University of Texas

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Alpha-Tocopherol in Plasma, Adipose (also: Lung, Skin, Muscle, Liver in the case of Death)		30 Days
Primary	Gamma-Tocopherol in Plasma, Adipose (also: Lung, Skin, Muscle, Liver in the case of Death)		30 Days
Primary	Vitamin E Metabolites in Plasma, Urine		30 Days
Primary	Malondialdehyde in Plasma, Urine (also: Lung, Skin, Muscle in the case of Death)		30 Days
Primary	Isoprostanes in Plasma, Urine (also: Lung, Skin, Muscle in the case of Death)		30 Days
Primary	Lipid Panel in Plasma and Triglyceride Concentration		30 Days
Primary	Liver Ultrasound		30 Days
Primary	Pulmonary Function Study Variables		30 Days
Primary	Cardiopulmonary Stress Test		30 Days
Secondary	Open Body Surface Area and Wound Healing		30 Days
Secondary	Weight		30 Days
Secondary	Basal Metabolic Rate		30 Days
Secondary	Diet History and Food Intake		30 Days
Secondary	Fluid Balance		30 Days
Secondary	Incidence of Acute Respiratory Distress Syndrome (ARDS)		30 Days
Secondary	Incidence of Pneumonia		30 Days
Secondary	Incidence of Atelectasis		30 Days
Secondary	Ventilator Variables (Compliance, Resistance, Work of Breathing, Number of Days Ventilated)		30 Days
Secondary	Pulmonary Status Variables (Spirometry, Blood Gas, Diffusion Constant, Pulmonary Capillary Surface Area)		30 Days